HK Stock Movement | GENSCRIPT BIO (01548) Extends Losses by Over 11% in Afternoon Session as Affiliate Legend Biotech Drops 7% Overnight

Stock News12-09

GENSCRIPT BIO (01548) saw its afternoon losses widen by more than 11%, falling 11.07% to HK$13.41 by the time of writing, with a turnover of HK$307 million. The decline follows an overnight drop of over 7% in its affiliate Legend Biotech (LEGN). Reports indicate that at the 2025 American Society of Hematology (ASH) annual meeting, Kite Pharma, a subsidiary of Gilead Sciences, unveiled updated clinical data for its next-generation CAR-T therapy, anito-cel. The candidate drug for multiple myeloma demonstrated a 96% overall response rate and a 74% complete response rate while maintaining strong safety.

Huatai Securities previously noted that Legend Biotech has narrowed its losses, with a clearer strategic roadmap. CARVYKTI generated sales of $1.332 billion in the first three quarters, including $524 million in Q3. Legend Biotech reported a net loss of $266 million for the first nine months, with Q3 losses shrinking to $40 million, marking significant year-on-year and sequential improvements. The firm remains optimistic about GENSCRIPT BIO's orderly profit growth and turnaround across its business segments.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1112969446?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-09 14:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1112969446","market":"sh","top_or_hot":-1,"title":"HK Stock Movement | GENSCRIPT BIO (01548) Extends Losses by Over 11% in Afternoon Session as Affiliate Legend Biotech Drops 7% Overnight","media":"Stock News","content":"<p>GENSCRIPT BIO (01548) saw its afternoon losses widen by more than 11%, falling 11.07% to HK$13.41 by the time of writing, with a turnover of HK$307 million. The decline follows an overnight drop of over 7% in its affiliate Legend Biotech (LEGN). Reports indicate that at the 2025 American Society of Hematology (ASH) annual meeting, Kite Pharma, a subsidiary of Gilead Sciences, unveiled updated clinical data for its next-generation CAR-T therapy, anito-cel. The candidate drug for multiple myeloma demonstrated a 96% overall response rate and a 74% complete response rate while maintaining strong safety.</p>\n<p>Huatai Securities previously noted that Legend Biotech has narrowed its losses, with a clearer strategic roadmap. CARVYKTI generated sales of $1.332 billion in the first three quarters, including $524 million in Q3. Legend Biotech reported a net loss of $266 million for the first nine months, with Q3 losses shrinking to $40 million, marking significant year-on-year and sequential improvements. The firm remains optimistic about GENSCRIPT BIO's orderly profit growth and turnaround across its business segments.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | GENSCRIPT BIO (01548) Extends Losses by Over 11% in Afternoon Session as Affiliate Legend Biotech Drops 7% Overnight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | GENSCRIPT BIO (01548) Extends Losses by Over 11% in Afternoon Session as Affiliate Legend Biotech Drops 7% Overnight\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-09 14:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GENSCRIPT BIO (01548) saw its afternoon losses widen by more than 11%, falling 11.07% to HK$13.41 by the time of writing, with a turnover of HK$307 million. The decline follows an overnight drop of over 7% in its affiliate Legend Biotech (LEGN). Reports indicate that at the 2025 American Society of Hematology (ASH) annual meeting, Kite Pharma, a subsidiary of Gilead Sciences, unveiled updated clinical data for its next-generation CAR-T therapy, anito-cel. The candidate drug for multiple myeloma demonstrated a 96% overall response rate and a 74% complete response rate while maintaining strong safety.</p>\n<p>Huatai Securities previously noted that Legend Biotech has narrowed its losses, with a clearer strategic roadmap. CARVYKTI generated sales of $1.332 billion in the first three quarters, including $524 million in Q3. Legend Biotech reported a net loss of $266 million for the first nine months, with Q3 losses shrinking to $40 million, marking significant year-on-year and sequential improvements. The firm remains optimistic about GENSCRIPT BIO's orderly profit growth and turnaround across its business segments.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000306685.HKD","symbol_name":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","start_time":0,"source_url":"","article_id":"1112969446","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1112969446","pubTimestamp":1765260257,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"GENSCRIPT BIO (01548) saw its afternoon losses widen by more than 11%, falling 11.07% to HK$13.41 by the time of writing, with a turnover of HK$307 million. The decline follows an overnight drop of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","BK4139":"生物科技","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","BK4505":"高瓴资本持仓","LEGN":"传奇生物","BK1583":"高瓴概念","BK1141":"生命科学工具和服务","BK1576":"医药外包概念","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","BK4585":"ETF&股票定投概念","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","BK4588":"碎股","01548":"金斯瑞生物科技"},"translate_title":"港股走势|金斯瑞生物(01548)午后跌幅扩大逾11%附属传奇生物隔夜跌7%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1,"LEGN":1},"content_text":"GENSCRIPT BIO (01548) saw its afternoon losses widen by more than 11%, falling 11.07% to HK$13.41 by the time of writing, with a turnover of HK$307 million. The decline follows an overnight drop of over 7% in its affiliate Legend Biotech (LEGN). Reports indicate that at the 2025 American Society of Hematology (ASH) annual meeting, Kite Pharma, a subsidiary of Gilead Sciences, unveiled updated clinical data for its next-generation CAR-T therapy, anito-cel. The candidate drug for multiple myeloma demonstrated a 96% overall response rate and a 74% complete response rate while maintaining strong safety.\nHuatai Securities previously noted that Legend Biotech has narrowed its losses, with a clearer strategic roadmap. CARVYKTI generated sales of $1.332 billion in the first three quarters, including $524 million in Q3. Legend Biotech reported a net loss of $266 million for the first nine months, with Q3 losses shrinking to $40 million, marking significant year-on-year and sequential improvements. The firm remains optimistic about GENSCRIPT BIO's orderly profit growth and turnaround across its business segments.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1112969446","isCrawlerRequest":true}